Education
About Us
Working with TipRanks
Follow Us
Xspray Pharma AB (SE:XSPRAY)
:XSPRAY
XSPRAY Stock Chart & Stats
kr31.00
kr0.60(1.95%)
At close: 4:00 PM EST
kr31.00
kr0.60(1.95%)
Day’s Range― - ―
52-Week Rangekr22.59 - kr64.10
Previous CloseN/A
Volume2.99K
Average Volume (3M)297.70K
Market Cap
€1.04B
Enterprise Valuekr1.88B
Total Cash (Recent Filing)€197.98M
Total Debt (Recent Filing)€148.91M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Feb 18, 2026EPS Estimate
1.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding41,742,340
10 Day Avg. Volume602,659
30 Day Avg. Volume297,696
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-5.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Xspray Pharma AB News
XSPRAY FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was kr22.59 and its highest was kr64.10 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is €1.04B.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is Feb 18, 2026 which is in 67 days.
How were Xspray Pharma AB’s earnings last quarter?
Xspray Pharma AB released its earnings results on Nov 05, 2025. The company reported -kr1.651 earnings per share for the quarter, the consensus estimate of -kr1.651 by kr0.
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate is 1.75.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 41,742,340 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Xspray Pharma AB reported an EPS of -kr1.651 in its last earnings report, expectations of -kr1.651. Following the earnings report the stock price went down -0.803%.
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in SE:XSPRAY
Company Description
Xspray Pharma AB
Xspray Pharma AB (XSPRAY) is a Swedish pharmaceutical company that specializes in developing improved versions of already approved and marketed drugs. The company focuses on creating novel formulations using its proprietary HyNap technology platform, which enhances the solubility and absorption of drugs. Xspray Pharma primarily targets the oncology sector, aiming to provide competitive alternatives to existing cancer treatments with better efficacy and safety profiles.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---